Funding to Drive Nanoscale Technology for Healthcare - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Funding to Drive Nanoscale Technology for Healthcare

ePT--the Electronic Newsletter of Pharmaceutical Technology

The UK’s Technology Strategy Board has partnered with the Engineering and Physical Sciences Research Council (EPSRC) to invest as mush as £9 million ($14.2 million) in grant funding with the aim of bringing proof-of-concept ideas to pilot technology demonstration for healthcare.

The Technology Strategy Board is a UK government body sponsored by the Department for Business, Innovation, and Skills (BIS), and charged with bringing together the business community, researchers, and the public sector to meet market needs and build the future economy. The specific goal of this project is to ensure that the healthcare sector adopts emerging novel nanoscale technology-enabled solutions by providing support to a commercialization route through innovative businesses.

The focus is on highly innovative, collaborative research in nanoscale technology-enabled solutions that deliver therapeutics and diagnostics. About £3 million ($4.75 million) is available for businesses (through the Technology Strategy Board), and £6 million ($9.49 million) is available for participation by academia (through the EPSRC). Collaborations to be considered must be business-led, but draw at least one partner from large or small businesses, academia, research, and technology organizations, or not-for-profit organizations. Projects can receive between £500,000 ($791,200) and £2 million ($3.16 million).

The Technology Strategy Board will accept applications from Nov. 1, 2011 until Dec. 13, 2011. Further information can be found here.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here